IN.gov | The Official Website of the State of Indiana

In the subgroup of patients on therapy with candesartan in combination with an ACEI and beta-adrenergic blocker, there was a significant risk reduction in the primary endpoint of CV death or HF hospitalization compared to patients on placebo. ... HTN, type 2 DM and nephropathy were randomized to irbesartan 300mg once daily, amlodipine 10mg once ... ................
................